Association between Ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients by Yang, Yongfeng et al.
RESEARCH Open Access
Association between Ghrelin gene (GHRL)
polymorphisms and clinical response to atypical
antipsychotic drugs in Han Chinese schizophrenia
patients
Yongfeng Yang
1,2†, Wenqiang Li
1,2†, Jingyuan Zhao
1, Hongxing Zhang
1,2, Xueqin Song
3, Bo Xiao
1,2, Ge Yang
1,2,
Chengdi Jiang
1,2, Dai Zhang
4, Weihua Yue
4* and Luxian Lv
1,2*
Abstract
Background: Ghrelin (GHRL) is a pivotal peptide regulator of food intake, energy balance, and body mass. Weight
gain (WG) is a common side effect of the atypical antipsychotics (AAPs) used to treat schizophrenia (SZ). Ghrelin
polymorphisms have been associated with pathogenic variations in plasma lipid concentrations, blood pressure,
plasma glucose, and body mass index (BMI). However, it is unclear whether GHRL polymorphisms are associated
with WG due to AAPs. Furthermore, there is no evidence of an association between GHRL polymorphisms and SZ
or the therapeutic response to AAPs. We explored these potential associations by genotyping GHRL alleles in SZ
patients and controls. We also examined the relation between these SNPs and changes in metabolic indices during
AAP treatment in SZ subgroups distinguished by high or low therapeutic response.
Methods: Four SNPs (Leu72Met, -501A/C, -604 G/A, and -1062 G > C) were genotyped in 634 schizophrenia
patients and 606 control subjects.
Results: There were no significant differences in allele frequencies, genotype distributions, or the distributions of
two SNP haplotypes between SZ patients and healthy controls (P > 0.05). There was also no significant difference
in symptom reduction between genotypes after 8 weeks of AAP treatment as measured by positive and negative
symptom scale scores (PANSS). However, the -604 G/A polymorphism was associated with a greater BMI increase
in response to AAP administration in both APP responders and non-responders as distinguished by PANSS score
reduction (P < 0.001). There were also significant differences in WG when the responder group was further
subdivided according to the specific AAP prescribed (P < 0.05).
Conclusions: These four GHRL gene SNPs were not associated with SZ in this Chinese Han population. The -604
G/A polymorphism was associated with significant BW and BMI increases during AAP treatment. Patients exhibiting
higher WG showed greater improvements in positive and negative symptoms than patients exhibiting lower
weight gain or weight loss.
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Schizophrenia (SZ) is a severe brain disorder afflicting
approximately 1% of the world’s population and often
leads to a lifetime of disability and emotional distress
[1]. Family, twin, and adoption studies strongly indicate
that genetics contribute to the etiology of SZ, probably
by transmission of multiple susceptibility genes each
exerting weak-to-moderate effects on predisposition
[2,3]. Many candidate susceptibility genes have been
identified, including the dopamine receptor D2, neure-
gulin1, and disrupted in schizophrenia 1 (DISC-1) [4-6].
Epidemiological studies have also revealed that people
with SZ are at greater risk for obesity, type 2 diabetes,
dyslipidemia, and hypertension than the general popula-
tion [7]. Recently, it was suggested that SZ patients are
at increased risk of metabolic problems and that the
associated symptoms are a serious threat to patient
health [8]. Metabolic problems are often triggered by
antipsychotic medication. Indeed, significant weight gain
is common in AAP-treated SZ patients, especially
patients administered clozapine, olanzapine, quetiapine,
or risperidone [9].
The peptide ghrelin (product of the GHRL gene) is an
important metabolic regulator produced by the stomach
and pancreas. Specific SNPs of GHRL have been associated
with variations in BMI, blood pressure, high-density lipo-
proteins, low-density lipoproteins, serum cholesterol,
blood glucose, and metabolic syndrome [10-14]. Ghrelin,
originally isolated from the rat stomach, stimulates food
intake and controls energy balance [15,16]. Studies on ani-
mal models revealed that GHRL increased food intake and
adiposity [17,18]. However, circulating GHRL levels were
decreased in obese individuals, and serum GHRL levels
were inversely correlated with BMI, suggesting that GHRL
is not directly involved in most cases of obesity [19,20].
Studies on the relationship between WG, circulating
GHRL, and AAP have yielded inconsistent findings.
Patients taking clozapine or olanzapine showed greater
WG than patients on other antipsychotics [21]. In one
study, plasma total GHRL and active GHRL were increased
significantly immediately after olanzapine treatment, but
the changes in BMI and body weight were not significant
after 6 months of treatment [22]. In contrast, another
study found that serum bioactive GHRL levels decreased
significantly from baseline after 4 weeks of olanzapine
monotherapy [23]. In humans, GHRL plays an important
role in the long-term regulation of body weight (BW) as
well as in the short-term regulation of appetite [19,21].
Ghrelin stimulated preadipocyte differentiation, increased
the BMI, and inhibited the anorexigenic effect of leptin
[24]. Drug altering GHRL f u n c t i o nm a yh a v ed i s t i n c t
short- and long-term effects on BMI.
The human GHRL gene is located on chromosome 3
(3p25-p26), and consists of 4 exons and 3 introns
[25,26]. Several SNPs in the coding region of prepro-
ghrelin have been described, but there is no known
specific association between genetic variations in the
human GHRL gene and SZ risk. However, region
3p25.1-26.1 is strongly associated with schizophrenia. In
addition to GHRL, this region contains SYN2, HRH1,
and GRM7, all candidate genes for schizophrenia. The
positive symptoms of schizophrenia are associated with
dysfunction in dopaminergic signaling, which is closely
associated with a GHRL mutation [27-29]. Previous stu-
dies demonstrated that SNPs in GHRL were associated
with high BMI; the Leu72Met allele was significantly
associated with BMI and coronary artery disease
[18,19,30], but this was not confirmed in other studies
[26,31,32].
In light of the increase metabolic syndrome symptoms
observed in SZ patients on AAPs, as well as the impor-
tant role of GHRL as a metabolic regulator and the asso-
ciation between GHRL SNPs and metabolic indices, we
hypothesized that (1) GHRL might be a candidate gene
for SZ and that (2) allelic variants of GHRL might be
associated with the propensity for BMI changes induced
by AAP treatment. In addition, we tested (3) whether a
putative relationship between GHRL SNPs and metabolic
effects was specific to individual AAP types. Finally, (4)
we examined if GHRL alleles influenced the clinical effi-
cacy of AAPs. To these ends, we genotyped four SNPs
and investigated whether they were associated with SZ
and the therapeutic and metabolic effects of AAPs in the
Han Chinese population.
Methods
The study group consisted of 634 diagnosed schizophre-
nic patients (332 males and 302 females; mean age: 27.14
± 7.53 years). Patients were unrelated Han Chinese born
and living in the North Henan province, and all their bio-
logical grandparents were of Han Chinese ancestry. Indi-
viduals with a history of severe medical complications,
organic brain disease, any concomitant major psychiatric
disorders, or substance dependence were excluded. All
patients were recruited from the Department of Psychia-
try of the Second Affiliated Hospital of Xinxiang Medical
U n i v e r s i t y ,P . R .C h i n a .T h ec o n s e n s u sd i a g n o s e sw e r e
conducted by at least two experienced psychiatrists
according to the Diagnostic and Statistical Manual of
Mental Disorders, fourth Edition (DSM-IV) [33]. The
patient group included paranoid (n = 309), catatonic (n =
50), collapse (n = 45), residual (67), and undifferentiated
(n = 163) schizophrenic types.
The control group consisted of 606 healthy subjects
(293 males and 313 females; mean age: 29.08 ± 7.80
years) recruited from communities and colleges within
the same region and matched to the patient group for
age, gender ratio, and Han ethnicity. Controls were
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Page 2 of 9recruited using a simple non-structured interview per-
formed by psychiatrists. Individuals with personal or
family histories of mental illness or neurological diseases
were excluded. The objectives and procedures of the
study were explained to all subjects and written
informed consent was obtained. The Ethical Committee
of the Department of Psychiatry of the Second Affiliated
Hospital of Xinxiang Medical University approved this
study.
Three hundred and eighty patients were evaluated
using the Positive and Negative Symptom Scale
(PANSS) [34] before and after an 8-week administration
of antipsychotic medications. Only those patients with
total PANSS scores ≥ 60 before treatment were
included. The reduction in PANSS scores from baseline
after the 8-week treatment regime was used to evaluate
the efficacy of each AAP. Patients were divided into 2
g r o u p sb a s e do nt h er e d u c t i o ni nP A N S Ss c o r e ,a
responder group exhibiting a > 50% reduction and
none-responder group exhibiting a ≤ 50% reduction
[35].
We excluded patients with incomplete clinical data. A
total of 569 patients were treated by monotherapy using
an AAP not previously prescribed. Patients were treated
with clozapine (n = 103, 100-700 mg/d), risperidone
(n = 181, 2-6 mg/d), olanzapine (n = 60, 5-20 mg/d),
quetiapine (n = 126, 400-750 mg/d), ziprasidone (n =
61, 80-160 mg/d), or aripiprazole (n = 38, 10-30 mg/d).
Body weight and BMI was measured before and after 4
weeks of AAP treatment. Individual BMIs were calcu-
lated as BMI = weight (kg)/height
2 (m).
Peripheral blood samples were obtained from the sub-
jects and genomic DNA was prepared using the QIAamp
DNA blood Mini Kit (QIAGEN, Hilden, Germany). Four
SNPs [rs696217 (Leu72Met), rs26802 (-501A/C), rs27647
(-604 G/A), and rs26311 (-1062 G > C)] were selected
according to the dbSNP database http://www.ncbi.nlm.
nih.gov/SNP/. The SNPs rs27647 and rs26311 are located
in the promoter region, rs26802 in intron 1, and
rs696217 in exon 3 of GHRL. All these SNPs effect GHRL
function and have been linked to metabolic symptoms.
The rs696217 amino-acid change (Leu72Met) affects the
tail of the pro-ghrelin molecule, but it is not known how
this affects GHRL expression or activity (Table 1). The
four SNPs were detected by polymerase chain reaction
(PCR)-based restriction fragment length polymorphism
(PCR-RFLP) analysis.
The primers of the four SNPs investigated are shown
in Table 1. The conditions used for PCR amplification
included an initial denaturation step at 94°C for 5 min,
followed by 36 cycles of 94°C for 30 s, 55-65°C for 30 s,
and 72°C for 1 min, followed by a final extension at 72°
C for 10 min. Small volumes (10 μl) of these PCR pro-
ducts were completely digested with 2U of restriction
enzyme (Dra I for -604 G/A, Mwo I for -501A/C, Bsr I
for Leu72Met, and Bcn I for -1062 G > C). The frag-
ments were separated on 2-4% agarose gels and visua-
lized under ultraviolet light after staining with ethidium
bromide.
The statistical power of the sample size was calculated
by the genetic power calculator (GPC, http://pngu.mgh.
harvard.edu/~purcell/gpc/cc2.html) [36]. Deviations in
the genotype counts from Hardy-Weinberg equilibrium
were tested using a c
2 goodness-of-fit test. Statistical
differences in genotypic, allelic, and haplotypic distribu-
tions between SZ and control subjects were evaluated
by the c
2 test with a significance level of 0.05. Odds
ratios (OR) and 95% confidence intervals (95% CI) were
calculated to evaluate the effects of different alleles on
SZ risk. Pair-wise linkage disequilibrium (LD) analysis
was applied to detect the inter-marker relationship
using D’ and r
2 values. Case-control association analysis
was performed by SHEsis software http://analysis.bio-x.
cn/myAnalysis.php[37], a powerful software platform for
analyses of LD, haplotype construction, and genetic
association at polymorphic loci. Associations between
response to a specific AAP and genotype were deter-
mined by t-tests and analysis of variance (ANOVA) tests
using SPSS 13.0 software. Results were considered sig-
nificant at P < 0.05 (two-tailed).
The size of our sample was sufficient to detect a sig-
nificant difference with a power of more than 70%
assuming an OR value for AA of 1.5 with a minor allele
frequency of 0.1 and type I error rate set at 0.05.
Table 1 SNPs and primers of PCRs and corresponding restriction enzymes
Marker Location Primer sequence (5’-3’) Product (bp) Annealing temperature (°C) RFLP Allele (bp)
rs27647 Promoter 5’-CACAGCAACAAAGCTGCACC-3’ 929 65 Dra I A(929)
5’-AAGTCCAGCCAGAGCATGCC-3’ G(664,265)
rs26802 Intron 1 5’-AGAACAAACGCCAGTCATCC-3’, 205 55 Mwo I A(205)
5’-GTCTTCCAGCCAGACAGTCC-3’ C(104,101)
rs696217 Exon 3 5’-GCTGGGCTCCTACCTGAGC-3’ 618 65 Bsr I T(618)
5’-GGACCCTGTTCACTGCCAC-3’ G(517,101)
rs26311 Promoter 5’-GGCAGCAGTCACGGACAATAAA-3’ 779 55 Bcn I G (572,252)
5’-CTCAGAAGAGGCATCCGCTAAA-3’ C(527,191,61)
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Four SNPs in the GHRL locus were analyzed: Leu72Met,
-501A/C, -604 G/A, and -1062 G > C. As shown in
Table 2, none of the genotype distributions of these four
SNPs showed significant deviation from Hardy-Wein-
berg equilibrium, and none of the allele frequencies or
the genotype distribution differed between patients and
controls (P >0 . 0 5 ) .T h e r ew a sa l s on os i g n i f i c a n ta s s o -
ciation between any allele or genotype and SZ when
patients were subdivided by gender (Table 3).
To further analyze the haplotype structure in our
sample, pair-wise linkage disequilibrium (LD) of the
four SNPs in the control group was computed using the
standardized measures D’ and r
2 values. There was strong
LD in Leu72Met and -501A/C, so haplotype analyses
were performed (Table 4). However, the haplotypes
constructed from two SNPs showed no significant differ-
ences between patients and controls (Table 5).
Of the 634 patients with SZ, 380 completed the PANSS
to assess psychopathological syndromes. The results
revealed that there were no significant differences in
PANSS score reduction among the different genotypes of
the four SNPs (-604 G/A, -501A/C, Leu72Met and -1062
G > C) after 8 weeks treatment with AAPs (Table 6).
However, in the responder group with the larger decreases
in PANSS scores (> 50%), there was a significant associa-
tion between BW and BMI increase (Table 7). The
responder group exhibited significantly greater BW and
BMI increases than none responders, and patients in spe-
cific AAP treatment groups with high weight gain showed
greater improvements than those with low weight gain
when subdivided according to drug (Table 8).
Table 2 Genotype and allele frequencies of four SNPs in GHRL gene between schizophrenia patients and healthy
controls
Marker N
a Genotype
b HWE P-value Allele
b P-value OR
c (95%CI)
rs696217 GG GT TT G T
Patients 634 427(0.684) 180(0.288) 17(0.027) 0.704 0.649 1034(0.829) 214(0.171) 0.773 1.03(0.83-1.27)
Controls 606 400(0.670) 184(0.308) 13(0.022) 0.123 984(0.824) 210(0.176)
rs26802 AA AC CC A C
Patients 634 534(0.842) 95(0.150) 5(0.008) 0.732 0.944 1163(0.917) 105(0.083) 0.922 1.01(0.76-1.35)
Controls 606 505(0.839) 93(0.154) 4(0.007) 0.900 1103(0.916) 101(0.084)
rs27647 AA AG GG A G
Patients 634 10(0.016) 133(0.210) 491(0.774) 0.773 0.410 153(0.121) 1115(0.879) 0.301 1.13(0.88-1.46)
Controls 606 5(0.008) 120(0.198) 480(0.793) 0.400 130(0.107) 1080(0.893)
rs26311 CC CG GG C G
Patients 634 253(0.402) 298(0.474) 78(0.124) 0.498 0.826 804(0.639) 454(0.361) 0.723 1.03(0.87-1.21)
Controls 606 234(0.387) 297(0.491) 74(0.122) 0.171 765(0.632) 445(0.368)
a Number of samples which are well genotyped
b Frequencies are shown in parenthesis
c Odds ratios of alleles were calculated for each reference vs. variant allele
Table 3 Genotype frequencies of the four SNPs interaction with gender
dbSNP ID Genotype Female Male
Patients Controls p-value Patients Controls p-value
rs696217 GG 224 191 0.689 203 209 0.896
GT 93 91 87 93
TT 11 7 6 6
rs26802 AA 279 247 0.306 255 258 0.723
AC 50 41 45 52
C C32 22
rs27647 AA 4 2 0.151 6 3 0.368
AG 77 51 56 69
GG 251 240 240 240
rs26311 CC 142 118 0.358 111 116 0.876
CG 150 139 148 158
GG 37 36 41 38
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schizophrenic patients were analyzed with nonparametric
tests. There was a significant association between BW and
BMI measured before and after 4-week AAP treatment
(P = 0.005 and 0.004 respectively). Patients with the -604
G/A exhibited significantly higher BWs and BMIs after
treatment (P = 0.028 and 0.011, respectively) (Table 9).
Similarly, paranoid SZ patients (n = 309) demonstrated
greater WG and BMI increases (P = 0.020 and 0.011,
respectively). In addition, there were significant differences
in the BW and BMI increases between G allele carriers
and homozygous allele A carriers in patients harboring
SNP-604 G/A (P = 0.039 and 0.013, respectively).
Discussion
The associations between GHRL polymorphisms and
SZ risk, changes in weight/BMI, and therapeutic
responses to AAPs were evaluated in a population of
SZ patients of Han Chinese ethnicity. While we found
no association between GHRL gene polymorphisms
and SZ susceptibility in this case-control study, analy-
sis did reveal significant BW and BMI increases during
AAP treatment in patients harboring the -604 G/A
polymorphism.
To our knowledge, no previous study has examined the
association between GHRL gene polymorphisms and sus-
ceptibility to SZ. Our study revealed no significant differ-
ences in allele and genotype frequency of four GHRL
SNPs between schizophrenic patients and controls even
when patients were subdivided by gender. Thus, GHRL is
not a likely SZ risk gene despite the fact that it is in a sus-
ceptibility locus (3p25-p26). Furthermore, we also exam-
ined paranoid SZ cases in light of the study by Scassellati
et al. [38]. Again, we found no significant differences in
the frequency of these four SNPs or the genotype distribu-
tion between paranoid patients and controls, but this
could reflect the relatively small sample size of paranoid
schizophrenic patients in our cohort. Furthermore, we
found no haplotypes with significantly higher frequency
between cases and controls. Therefore, we suggest that
GHRL is not a predisposing gene for SZ in the Chinese
Han population.
In the present study, no association between PANSS
reduction during AAP treatment and GHRL gene poly-
morphisms was found. However, the magnitude of the
PANSS score reduction was significantly associated with
the increase in BW and BMI during AAP treatment.
Meanwhile, the reduction rate of PANSS total score in
responder and none-responder groups had significant
association with BW and BMI increase. The same finding
was also revealed when patients were subdivided accord-
ing the specific AAP taken. Atypical antipsychotics
induced weight gain in a significant fraction of SZ
patients [9], but factors that are predictive of weight gain
during AAP therapy are unclear. We found that patients
exhibiting the greatest weight gains while receiving olan-
zapine, risperidone, clozapine, or quetiapine also showed
greater improvements in symptoms than those showing
lower weight gain. This result is in partial accord with a
previous study that found olanzapine-induced weight
gain correlated negatively with baseline BMI and posi-
tively with clinical global improvement and the length of
olanzapine treatment [39].
The GHRL gene may be a promising candidate under-
lying AP-induced weight gain [40]. We found significant
differences between the three -604 G/A genotypes, with
patients harboring AA showing the greatest weight gain
and increase in BMI. In addition to BMI, -604 G/A has
been linked to variations in blood pressure [12]. Pre-
vious studies have also reported that the Leu72Met
polymorphism was significantly associated with BMI
[10,11]. However, we found no association between
Leu72Met polymorphisms and the AAP-induced BMI
increase, consistent with previous findings [26,31,32]. In
addition to the significant association between the AA
genotype and BMI, we also found that paranoid SZ
patients demonstrated higher weight gain than patients
with other subtypes of SZ, including catatonic, collapse,
residual, and undifferentiated patients. Therefore, our
results provide suggestive ev i d e n c ef o ral i n kb e t w e e n
-604 G/A and metabolic syndrome in paranoid SZ.
Table 4 Pairwise linkage disequilibrium among four SNPs
in the GHRL gene (D’ values is shown above and r
2
values below the diagonal)
rs696217 rs26802 rs27647 rs26311
rs696217 0.901 0.004 0.261
rs26802 0.016 0.175 0.193
rs27647 0.000 0.000 0.116
rs26311 0.025 0.006 0.001
Table 5 Estimated haplotype frequencies and case-control haplotype results
SNP Haplotype Frequencies c
2 P-value OR (95%CI) Global
Cases Controls c
2 P-value
rs696217–rs26802 G-A 930.15(0.745) 883.02(0.742) 0.007 0.933 1.008(0.840~1.209) 0.022 0.989
G-C 103.85(0.083) 97.98(0.082) 0.004 0.952 1.009(0.756~1.346)
T-A 213.85(0.171) 205.98(0.173) 0.020 0.888 0.985(0.798~1.216)
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SNP Genotype N Before treatment After 8 weeks treatment Reduction rate (%)*
Total** P
a N
b G
c total P
a N
b G
c
rs27647 GG 292 88.06 ± 21.64 24.49 ± 6.63 21.46 ± 8.00 42.11 ± 12.34 45.84 ± 12.63 10.87 ± 3.69 11.65 ± 4.85 23.32 ± 6.33 0.72 ± 0.19
GA+AA 88 87.38 ± 23.51 23.05 ± 6.92 22.81 ± 8.28 41.52 ± 13.4 45.40 ± 10.86 10.68 ± 3.53 12.24 ± 5.05 22.48 ± 4.88 0.72 ± 0.19
P 0.799 0.076 0.169 0.702 0.767 0.672 0.321 0.250 0.988
rs26802 AA 322 88.61 ± 22.47 24.35 ± 6.80 21.74 ± 8.26 42.52 ± 12.76 45.91 ± 12.47 10.90 ± 3.76 11.76 ± 4.97 23.25 ± 6.17 0.72 ± 0.19
AC+CC 58 83.97 ± 19.33 23.09 ± 6.16 21.91 ± 7.00 38.97 ± 11.20 44.79 ± 10.85 10.43 ± 2.96 11.93 ± 4.49 22.43 ± 5.15 0.72 ± 0.18
P 0.140 0.187 0.882 0.048 0.524 0.371 0.805 0.341 0.929
rs696217 GG 253 87.91 ± 22.94 24.23 ± 6.53 21.66 ± 8.36 42.02 ± 13.15 45.09 ± 11.31 10.63 ± 3.60 11.61 ± 4.70 22.85 ± 5.34 0.73 ± 0.18
GT+TT 120 87.65 ± 19.38 24.11 ± 6.96 21.82 ± 7.36 41.73 ± 10.91 45.97 ± 11.41 11.01 ± 3.31 11.74 ± 4.70 23.22 ± 6.10 0.71 ± 0.20
P 0.915 0.870 0.864 0.834 0.484 0.329 0.798 0.555 0.309
rs26311 CC 153 87.25 ± 22.59 24.09 ± 6.84 21.58 ± 7.52 41.58 ± 13.06 45.30 ± 11.10 10.85 ± 3.70 11.52 ± 4.52 22.93 ± 5.35 0.72 ± 0.19
GG+GC 223 87.66 ± 21.04 24.09 ± 6.59 21.74 ± 8.36 41.83 ± 11.82 46.01 ± 13.04 10.79 ± 3.63 11.96 ± 5.15 23.25 ± 6.49 0.72 ± 0.19
P 0.857 0.998 0.845 0.848 0.582 0.884 0.385 0.619 0.883
*reduction rates of PANSS total scores; ** total scores;
a Positive score;
b negative score;
c general pathology score
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9Conclusion
While we did not find an association between GHRL
alleles and susceptibility to SZ in the Chinese Han
population, the -604 G/A polymorphism, and particu-
larly the AA genotype, was associated with larger
increases in BW and BMI in SZ patients under
treatment with AAPs. Surprisingly, patients showing
the greatest weight gain also showed the greatest
improvements in symptoms. In order to more precisely
define the impact of antipsychotic medications on
metabolic parameters, control of patient subtype, sam-
ple size, as well as monitoring of multiple metabolic
Table 7 The BW and BMI change in responder group and none-responder groups
Two group
a N BW change
b (x ± s) kg BMI change
c(x ± s)
responder group 339 0.68 ± 4.00 0.27 ± 1.47
none-responder group 41 -1.13 ± 2.35 -0.42 ± 0.87
P-value 0.000 0.000
a Patients were divided into 2 groups based on reduction rates of PANSS total scores, namely, responder group (> 50%) and none-responder group (≤ 50%)
b Body weight change = body weight (4-week) - body weight(0 week)
c BMI change = BMI (4-week) - BMI (0 week)
Table 8 The BW and BMI change in responder group and none-responder groups when subdivided according to
different AAPs (x ± s)
Two groups
a AAP
b N BW change (kg) P-value BMI change P-value
responder group clozapine 63 0.60 ± 3.94 0.012 0.21 ± 1.41 0.009
risperidone 115 1.20 ± 3.71 0.46 ± 1.41
olanzapine 25 1.94 ± 4.47 0.76 ± 1.68
quetiapine 76 1.01 ± 3.41 0.37 ± 1.26
ziprasidone 32 -1.66 ± 4.78 -0.60 ± 1.74
aripiprazole 26 -0.67 ± 4.42 -0.19 ± 1.49
none-responder group clozapine 7 -1.57 ± 2.30 0.917 -0.55 ± 0.80 0.834
risperidone 11 -1.18 ± 1.99 -0.47 ± 0.79
olanzapine 5 -0.60 ± 1.82 -0.18 ± 0.62
quetiapine 8 -0.44 ± 2.87 -0.16 ± 1.07
ziprasidone 6 -1.5 ± 2.74 -0.56 ± 0.95
aripiprazole 3 -1.8 ± 3.69 -0.73 ± 1.42
a responder group and none-responder group
b atypical antipsychotics
Table 9 The association analysis of BW and BMI in four SNPs
SNP Genotype BW(0 week, kg) BW(4 week, kg) BW change (kg) BMI(0 week) BMI(4 week) BMI change
rs27647 GG 62.69 ± 11.86 63.16 ± 11.19 0.55 ± 3.85 22.65 ± 3.60 22.84 ± 3.44 0.21 ± 1.42
AG 62.85 ± 12.44 62.87 ± 11.88 -0.18 ± 3.35 22.16 ± 3.59 22.13 ± 3.48 -0.04 ± 1.18
AA 58.4 ± 7.40 61.39 ± 10.25 2.61 ± 3.46 21.4 ± 2.91 23.05 ± 3.71 1.15 ± 1.21
P-value 0.426 0.810 0.028* 0.392 0.181 0.011*
rs26802 AA 62.53 ± 12.13 62.90 ± 11.33 0.40 ± 3.79 22.54 ± 3.62 22.68 ± 3.45 0.17 ± 1.39
AC 63.35 ± 10.90 64.40 ± 11.28 0.87 ± 3.36 22.51 ± 3.54 22.95 ± 3.55 0.30 ± 1.21
CC 59.70 ± 9.78 56.8 ± 6.30 -2.9 ± 6.07 21.66 ± 2.03 20.68 ± 1.28 -0.97 ± 2.17
P-value 0.572 0.163 0.247 0.839 0.275 0.269
rs696217 GG 62.16 ± 11.75 62.77 ± 11.29 0.62 ± 3.60 22.33 ± 3.45 22.58 ± 3.37 0.24 ± 1.30
GT 63.57 ± 12.05 63.67 ± 11.08 0.10 ± 3.85 22.83 ± 3.57 22.86 ± 3.34 0.05 ± 1.41
TT 63.75 ± 15.14 63.67 ± 14.83 -0.08 ± 6.49 23.60 ± 6.07 23.60 ± 6.08 0.002 ± 2.51
P-value 0.446 0.589 0.319 0.358 0.676 0.254
rs26311 GG 63.30 ± 12.10 63.09 ± 10.36 0.41 ± 3.39 23.13 ± 3.74 23.12 ± 3.43 0.15 ± 1.28
GC 62.29 ± 12.25 62.89 ± 11.32 0.49 ± 3.90 22.63 ± 3.75 22.86 ± 3.48 0.20 ± 1.43
CC 62.77 ± 11.52 63.24 ± 11.65 0.41 ± 3.71 22.21 ± 3.34 22.39 ± 3.44 0.16 ± 1.34
P-value 0.792 0.925 0.804 0.343 0.344 0.765
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importance.
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